Review of tocilizumab in the treatment of rheumatoid arthritis

Biologics: Targets and Therapy

Volumn 2, Issue 1, 2008, Pages 75-82

  Okuda, Yasuaki ^a  

^a Dohgo Spa Hospital   (Japan)

Author keywords

Amyloidosis; Biologics; Interleukin 6; Rheumatoid arthritis; Tocilizumab; Treatment

Indexed keywords

EID: 77950263939     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s1828     Document Type: Review

References (25)

1. Choy EH, Isenberg DA, Garrood T, et al. 2002. Therapeutic benefi t of blocking interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum, 46:3143-50.
2. Fisman EZ, Benderly M, Esper RJ, et al. 2006. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol, 98:14-18.
3. Hagiwara K, Nishikawa T, Isobe T, et al. 2004. IL-6 plays a critical role in synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinfl ammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun, 314:363-9.
4. Hagiwara K, Nishikawa K, Sugamata Y, et al. 2005. Essential role of STAT3 in cytokine-driven NF-κB-mediated serum amyloid A gene expression. Gene Cells, 10:1051-63.
5. Hashimoto J, Garnero P, Miyasaka N, et al. 2007. Early changes in biochemical markers of cartilage turnover and synovial inflammation after tocilizumab monotherapy predict the one-year radiographic progression in patients with early rheumatoid arthritis. Mod Rheumatol, 17:S78
6. Hirano T, Yasukawa K, Harada H, et al. 1986. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature, 324:73-6.
7. Kiortsis DN, Mavridis AK, Filippatos TD, et al. 2006. Effects of infl iximab treatment on lipoprotein profi le in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol, 33:921-3.
8. Kotake S, Sato K, Kim KJ, et al. 1996. Interleukin-6 and soluble interleukin-6 receptors in the synovial fl uids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res, 11:88-95.
9. Lubberts E, Koenders MI, Oppers-Walgreen B, et al. 2004. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint infl ammation, cartilage destruction, and bone erosion. Arthritis Rheum, 50:650-9.
10. Maini RN, Taylor PC, Szechinski J, et al. 2006. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum, 54:2817-29.
11. Mihara M, Takagi Y, Takeda Y, et al. 1998. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol, 112:397-402.
12. Morgan ME, Flierman R, van Duivenvoorde LM, et al. 2005. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum, 52:2212-21.
13. Nakahara H, Song J, Sugimoto M, et al. 2003. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor (VEGF) production in rheumatoid arthritis. Arthritis Rheum, 48:1521-9.
14. Nishimoto N, Maeda K, Kuritani T, et al. 2003. Toxicity, pharmacokinetics, and dose fi nding study of repetitive treatment with humanized antiinterleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol, 30:1426-35.
15. Nishimoto N, Yoshizaki K, Miyasaka N, et al. 2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum, 50:1761-9.
16. Nishimoto N, Miyasaka N, Yamamoto K, et al. 2006a. Effi cacy and safety of tocilizumab in monotherapy, an anti-IL-6 receptor monoclonal antibody, in patients with active rheumatoid arthritis: results from a 24 week double-blind phase III study. Ann Rheum Dis, 65 (Suppl II):59
17. Nishimoto N, Miyasaka N, Yamamoto K, et al. 2006b. Consistent clinical response resulted from three Japanese randomized controlled trials of tocilizumab, humanized anti-IL-6 receptor antibody, in active rheumatoid arthritis (RA) patients. Arthritis Rheum, 54:S410
18. Nishimoto N, Hashimoto J, Miyasaka N, et al. 2007. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefi t from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis, 66:1162-7.
19. Ogawa J, Harigai M, Akashi T, et al. 2006. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis, 65:1667-9.
20. Okuda Y, Takasugi K. 2006. Successful use of a humanized anti-interleukin-6 antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum, 54:2997-3000.
21. Okuda Y, Ohnishi M, Matoba K, et al. 2007. Clinical evaluation of anticytokine therapies for AA amyloidosis complicating rheumatoid arthritis-in view of suppression of SAA levels. Mod Rheumatol, 17:S81
22. Roach DR, Bean AG, Demangel C, et al. 2002. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol, 168:4620-7.
23. Roux-Lombard P, Eberhardt K, Saxne T, et al. 2001. Cytokines, metalloproteinases, their inhibitors and cartilage oligometric matrix protein: relationship to radiological progression and infl ammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology, 40:544-51.
24. Ward LD, Howlett GJ, Discolo G, et al. 1994. High affi nity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem, 269:23286-9
25. Yoshizaki K, Nakagawa T, Kaieda T, et al. 1982. Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. J Immunol, 128:1296-301